A typical example is the monitoring of acquired resistance in NSCLC using cfDNA after epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) target therapy, such as the C797S, T790M, L858R, and Del19 EGFR variants [100]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.